Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 6/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 5/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.36 |
| ▸ | PKM | P14618 | 3/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29364718 | 1.00 | LMNA (0.51) | LMNAKDM4EKMT2AMEN1GAA | |
| SCHEMBL21647585 | 0.77 | KDM4E (0.41) | LMNAKDM4EKMT2AMEN1HSD17B10 | |
| SCHEMBL29715836 | 0.77 | KDM4E (0.41) | LMNAKDM4EKMT2AMEN1HSD17B10 | |
| SCHEMBL26688411 | 0.74 | KDM4E (0.55) | LMNAKDM4EKMT2AMEN1GAA | |
| SCHEMBL25209171 | 0.74 | KDM4E (0.55) | LMNAKDM4EKMT2AMEN1GAA | |
| SCHEMBL25233992 | 0.73 | MAPT (0.40) | LMNAKDM4EKMT2AMEN1GAA | |
| SCHEMBL22346715 | 0.73 | KDM4E (0.53) | LMNAKDM4EKMT2AMEN1MAPT | |
| SCHEMBL26688486 | 0.72 | TUBB4A (0.41) | LMNAKDM4EKMT2AMEN1HSD17B10 | |
| SCHEMBL25257553 | 0.72 | LMNA (0.55) | LMNAKDM4EKMT2AMEN1GAA | |
| SCHEMBL21647551 | 0.72 | KDM4E (0.38) | LMNAKDM4EKMT2AMEN1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230374017-A1 | COMPOSITIONS AND METHODS FOR ACTIVATING PYRUVATE KINASE | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2023-11-23 | — | — | US | disclosed |
| US-20230374017-A1 | COMPOSITIONS AND METHODS FOR ACTIVATING PYRUVATE KINASE | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2023-11-23 | — | — | US | disclosed |
| US-20230374017-A1 | COMPOSITIONS AND METHODS FOR ACTIVATING PYRUVATE KINASE | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2023-11-23 | — | — | US | disclosed |
| CN-116249531-A | Compositions and methods for activating pyruvate kinase | 密执安大学评议会 | 2023-06-09 | — | — | CN | disclosed |
| EP-4185293-A1 | COMPOSITIONS AND METHODS FOR ACTIVATING PYRUVATE KINASE | The Regents of The University of Michigan (US) | 2023-05-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230374017-A1 | COMPOSITIONS AND METHODS FOR ACTIVATING PYRUVATE KINASE | PCK1, PDK2, PDK1 | LMNA 1036/4885KDM4E 1883/4885KMT2A 1195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.